TLDR
- Shares of Vera Therapeutics increased 4% to $35.39 following the release of positive two-year ORIGIN3 trial results for Trutakna
- The kidney drug demonstrated the ability to slow kidney function decline to rates comparable with normal aging in IgA nephropathy patients
- The biotech company intends to submit a supplemental Biologics License Application during Q4 for full regulatory approval
- TD Cowen maintained its Buy recommendation with a $78 price objective after reviewing the clinical data
- Despite Tuesdays gain, VERA shares remain down 34% year-to-date amid competition from Vertex and Otsuka
Vera Therapeutics experienced a 4% share price increase to $35.39 on Tuesday following the publication of two-year clinical data from the ORIGIN3 study evaluating Trutakna, providing a positive catalyst for a stock that has faced headwinds throughout 2026.
Vera Therapeutics, Inc., VERA
The clinical trial enrolled participants diagnosed with immunoglobulin A nephropathy, a progressive kidney disease characterized by abnormal IgA antibody deposits that impair the glomerulis filtration capacity. Study findings demonstrated that Trutakna reduced the pace of kidney deterioration to levels seen in normal physiological aging, representing a significant therapeutic achievement.
Discover more
Access Premium News
Finance
Compare Exchange Rates
The annualized estimated glomerular filtration rate (eGFR) slope difference compared to placebo measured +5.0 mL/min/year. Treatment with Trutakna resulted in a two-year annualized eGFR decline of merely -0.6 mL/min/year, aligning with rates observed in individuals without kidney disease.
TD Cowen confirmed its Buy recommendation and maintained a $78 price objective following the data release, describing the kidney function results as among the most impressive outcomes from any Phase 3 IgAN clinical trial conducted to date.
This figure also exceeded the +4.5 mL/min/year placebo-adjusted advantage demonstrated by competing therapy Voyxact, although TD Cowen noted the differential may be within expected measurement variance.
Study participants additionally experienced improvements in critical disease biomarkers, including decreased proteinuria and hematuria. Dr. Richard Lafayette, a Stanford nephrology professor who served as a trial investigator, stated the findings offer robust evidence that Trutakna can substantially lower the long-term probability of requiring dialysis, kidney transplantation, or facing mortality.
Path to Complete FDA Authorization
The FDA granted Trutakna accelerated approval status in July, predicated on its demonstrated capacity to reduce urinary protein levels. To achieve full regulatory approval, Vera must now provide confirmatory evidence demonstrating sustained clinical advantages.
The pharmaceutical company expects to submit its supplemental Biologics License Application during the fourth quarter. Matt Skelton, Chief Commercial Officer, reported that within the initial 10 weeks post-launch, Vera collected over 350 patient enrollment forms and has begun receiving reimbursement claims from payers.
Wall Street analyst price projections span from $34 to $100, with the overall consensus rating classified as Strong Buy. Raymond James upheld its Strong Buy stance with an $84 price target, while Goldman Sachs maintains a Buy rating at an $80 objective after a modest reduction. H.C. Wainwright adjusted its target downward to $90 from $125, referencing competitive clinical results from an alternative treatment.
Market Competition Continues
Notwithstanding Tuesdays advance, VERA shares have declined 34% since the start of the year, pressured by an increasingly competitive IgAN therapeutic landscape.
Otsuka brought Voyxact to market in late 2025 via the accelerated approval pathway. Although both medications address the identical indication, Voyxact inhibits a single complement protein, whereas Trutakna simultaneously targets two distinct proteins in the complement cascade.
Vertex is advancing povetacicept, its own dual-pathway inhibitor, having received BLA acceptance for accelerated approval consideration with a regulatory decision deadline of November 30. Shares of competitor Vertex declined 1% on Tuesday.
The company maintains a net cash position with cash reserves exceeding total debt, a financial strength that both TD Cowen and InvestingPro identified as strategically important for a clinical-stage biotechnology enterprise.
Discover more
Open Trading Account
Compare Credit Cards
Take Economics Courses
The post Vera Therapeutics (VERA) Stock Surges Following Promising ORIGIN3 Trial Results appeared first on Blockonomi.